Evidence map›Paper›PMID 35778630›Full record

ReviewJapanese journal of radiology2022

Up-to-date evidence on image-guided thermal ablation for metastatic lung tumors: a review.

Yusuke Matsui, Koji Tomita, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Kazuaki Munetomo, Shoma Nagata, Toshihiro Iguchi, Takao Hiraki

Open access · hybridAbstract readReview
In one paragraph

Review in Japanese journal of radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Changes in Respiratory Function over Time after Radiofrequency Ablation for Lung Tumors.Interventional radiology (Higashimatsuyama-shi (Japan) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yusuke MatsuiDepartment of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. y-matsui@okayama-u.ac.jp.ORCID http://orcid.org/0000-0001-7548-7886
Koji TomitaDepartment of Radiology, Okayama University Hospital, Okayama, Japan.
Mayu UkaDepartment of Radiology, Okayama University Hospital, Okayama, Japan.
Noriyuki UmakoshiDepartment of Radiology, Okayama University Hospital, Okayama, Japan.
Takahiro KawabataDepartment of Radiology, Okayama University Hospital, Okayama, Japan.
Kazuaki MunetomoDepartment of Radiology, Okayama University Hospital, Okayama, Japan.
Shoma NagataDepartment of Radiology, Okayama University Hospital, Okayama, Japan.
Toshihiro IguchiDepartment of Radiological Technology, Faculty of Health Sciences, Okayama University, Okayama, Japan.
Takao HirakiDepartment of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Okayama University Hospital · JPOkayama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this review was to summarize the latest evidence on image-guided thermal ablation therapies for lung metastases. PubMed was used to search for relevant articles that reported the oncological outcomes of thermal ablation for metastatic lung tumors, and those published in 2010 or later were selected for review. Ablative therapies were applied for lung metastases from various types of primary tumors, but most commonly colorectal ones. Radiofrequency ablation (RFA) was the most evaluated technique, followed by microwave ablation (MWA). The local control rates of ablative therapies were generally favorable, approximately 80-90% in many studies. Representative studies demonstrated promising overall survival rates of approximately 50% or higher 5 years after ablation for lung metastases from colorectal cancer or mixed types of primary tumors. Nevertheless, the survival outcomes varied depending on the type of primary tumor and background factors of patients such as other metastases and comorbidities. Several studies had aimed to compare the outcomes of various ablative therapies such as RFA, MWA, and cryoablation; however, conclusive data are not yet available to determine the most appropriate ablation modality for lung metastases. Further data accumulation is needed, especially for long-term outcomes and comparisons with other therapies.

Indexed as

Ablation TechniquesCatheter AblationCryosurgeryLiver NeoplasmsLung NeoplasmsRadiofrequency AblationHumansSurvival RateTreatment OutcomeAblationLungMetastasisPulmonary

Identifiers

PMID35778630
PMCPMC9529706
OpenAlexW4283774038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.